Trial Outcomes & Findings for The Vertos MILD™ Preliminary Patient Evaluation Study (NCT NCT00749073)

NCT ID: NCT00749073

Last Updated: 2013-04-10

Results Overview

Clinical relevance established by change of two points or more on a ten point scale where zero represents no pain and ten represents worst pain imaginable. Mean change from baseline to Month 6 was reported with a positive number representing the baseline value minus the 6 month value.

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

10 participants

Primary outcome timeframe

Baseline and Six Months

Results posted on

2013-04-10

Participant Flow

Study enrolled between September 2008 and January 2009. Recruitment derived from patient pool of complex cases, all with confirmed presence of hypertrophic ligament, wait-listed for decompression laminectomy.

Participant milestones

Participant milestones
Measure
Mild Percutaneous Lumbar Decompression
The single group in this pilot study included ten patients treated for lumbar spinal stenosis of the central canal using the mild device kit to perform minimally invasive percutaneous decompression.
Overall Study
STARTED
10
Overall Study
COMPLETED
10
Overall Study
NOT COMPLETED
0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

The Vertos MILD™ Preliminary Patient Evaluation Study

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Mild Percutaneous Lumbar Decompression
n=10 Participants
The single group in this pilot study included ten patients treated for lumbar spinal stenosis of the central canal using the mild device kit to perform minimally invasive percutaneous decompression.
Age, Categorical
<=18 years
0 Participants
n=5 Participants
Age, Categorical
Between 18 and 65 years
6 Participants
n=5 Participants
Age, Categorical
>=65 years
4 Participants
n=5 Participants
Age Continuous
62.9 years
STANDARD_DEVIATION 12.84 • n=5 Participants
Sex: Female, Male
Female
2 Participants
n=5 Participants
Sex: Female, Male
Male
8 Participants
n=5 Participants
Region of Enrollment
Canada
10 participants
n=5 Participants

PRIMARY outcome

Timeframe: Baseline and Six Months

Population: All available treated patients at six months post treatment. Mean change from baseline to Month 6 was reported.

Clinical relevance established by change of two points or more on a ten point scale where zero represents no pain and ten represents worst pain imaginable. Mean change from baseline to Month 6 was reported with a positive number representing the baseline value minus the 6 month value.

Outcome measures

Outcome measures
Measure
Mild Percutaneous Lumbar Decompression
n=10 Participants
The single group in this pilot study included ten patients treated for lumbar spinal stenosis of the central canal using the mild device kit to perform minimally invasive percutaneous decompression.
Changes in Back Pain as Measured by a 10-point Visual Analog Scale (VAS).
3.3 units on a scale
Standard Deviation 2.95

PRIMARY outcome

Timeframe: Baseline and Month 6

Population: All treated patients having six month follow-up were included.

Oswestry Disability Index (ODI) is used to measure permanent functional disability through a series of questions which characterize the disturbance of activities of daily living resulting from chronic back pain. The questionnaire is divided into 10 topics including pain intensity , personal care, lifting, walking, sitting, standing, sleeping, social life, traveling and employment/homemaking. Each topic is rated 0 (no pain or no limitation) to 5 (high pain or very limited physically). The worst possible score is 50 (100% disability) and best would be zero (0% disability), thus a higher ODI score indicates greater disability.

Outcome measures

Outcome measures
Measure
Mild Percutaneous Lumbar Decompression
n=10 Participants
The single group in this pilot study included ten patients treated for lumbar spinal stenosis of the central canal using the mild device kit to perform minimally invasive percutaneous decompression.
Function as Measured Subjectively by the Oswestry Disability Index Patient Questionnaire
19.4 units on a scale
Standard Deviation 22.73

PRIMARY outcome

Timeframe: Baseline and Six months

Population: All available treated patients with six month follow-up.

The 12-question SF-12v2 Health Survey is a validated generic measure of health status \& outcomes, as opposed to one that targets a specific age, disease, or treatment group. The Physical Component Summary (PCS)takes into account the correlations among the Physical Functioning (PF), Role Physical (RP), Bodily Pain (BP), General Health (GH), and Vitality (VT)SF-12v2 Health Survey scales to show the broad impact on PCS. Norm-based scoring is used so each scale has the same mean (50 points) and the same standard deviation (10 points) as the general US population in 1998. Scores below 50 indicate a decline in health status, with lower scores representing worse health status. Minimally Important Difference (MID) is a measure of true clinical relevance of a difference, with suggested MID for the Physical Component Summary (PCS) being 2 to 3 points. Change from baseline to 6 months is presented, where a positive value represents the 6 month value minus the baseline value.

Outcome measures

Outcome measures
Measure
Mild Percutaneous Lumbar Decompression
n=10 Participants
The single group in this pilot study included ten patients treated for lumbar spinal stenosis of the central canal using the mild device kit to perform minimally invasive percutaneous decompression.
Quality of Life as Measured by the PCS Subscale of the Short-form 12 Question (SF-12) Survey.
6.14 units on a scale
95% Confidence Interval 9.31 • Interval 4.4 to 11.74

Adverse Events

Mild Percutaneous Lumbar Decompression

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

VP Clinical, Regulatory, Quality

Vertos Medical

Phone: 9493490008

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place

Restriction type: LTE60